pharmaceuticals

IPO

Proteostasis Therapeutics Closes in on IPO

Proteostasis Therapeutics has filed an amended S-1 form with the U.S. Securities and Exchange Commission (SEC) for its initial public offering (IPO). This company expects to price its 3.85 million ...
Read Full Story »
Medicine pills

Short Sellers Increase Bets in Major Pharma

The short interest data have been released for the January 29 settlement date. Pharmaceutical companies are usually involved in a lengthy process in getting their drug candidates to market through ...
Read Full Story »
IPO

Corvus Pharma Prepares for IPO

Corvus Pharmaceuticals has filed an amended S-1 form with the U.S. Securities and Exchange Commission (SEC) for its initial public offering (IPO). No pricing details were given in the filing. ...
Read Full Story »
Test tubes

Reata Pharmaceuticals Gears Up for IPO

Reata Pharmaceuticals has filed an amended S-1 form with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO). No pricing details were given in the filing, ...
Read Full Story »
Pfizer

Why Merrill Lynch Sees Big Upside in Pfizer (and Even More With Allergan)

Pfizer Inc. (NYSE: PFE) offers a compelling valuation, an attractive dividend yield and good pipeline optionality. This is in part due to its merger with Allergan PLC (NYSE: AGN), which ...
Read Full Story »
automatic inspection machine

Regeneron Falls on Missed Earnings

Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) reported its fourth-quarter financial results before the markets opened on Tuesday. The company had $2.83 in earnings per share (EPS) on $1.10 billion in revenue, ...
Read Full Story »
Prescription drugs

4 Big Dividend Pharmaceutical Stocks to Buy That Are Very Cheap Now

If you ever want to look for value in a sector in the stock market, then when you see Congress calling in some of the top companies to scold them ...
Read Full Story »
Medicine pills

How Analysts View Pfizer and Merck After Earnings

Pfizer Inc. (NYSE: PFE) and Merck & Co. Inc. (NYSE: MRK) released their most recent earnings reports last week. As a result, analysts weighed in on both of these pharmaceutical ...
Read Full Story »
biotech word cloud

Top 4 BioPharma Movers of the Week

Over the past week, a few biotech companies made absolutely massive runs, either up and down. In the past year, the health care sector was on fire from positive trials, ...
Read Full Story »
IPO

Mapi Pharma Closes in on IPO

Mapi Pharma has registered with the U.S. Securities and Exchange Commission (SEC) for its initial public offering (IPO), and announced it the expected pricing terms in its most recent filing. ...
Read Full Story »
IPO

Therapure Biopharma Postpones IPO

The initial public offering (IPO) market has grown cold as global markets have been sliding in 2016, and many companies are choosing to postpone their IPOs for more favorable market ...
Read Full Story »
automatic inspection machine

Will Sinovac Go Through With This Buyout?

Sinovac Biotech Ltd. (NASDAQ: SVA) was riding high early Thursday morning, following the offer for a potential buyout, but it looks like this company doesn’t want to take the bait. ...
Read Full Story »
coins

Merck Trips Up Over Mixed Earnings

Merck & Co. Inc. (NYSE: MRK) reported its fourth-quarter financial results before the markets opened Wednesday. The company had $0.93 in earnings per share (EPS) on $10.21 billion in revenue, ...
Read Full Story »
cancer

Beigene Gears Up for IPO With Pricing Details

Beigene has filed an amended S-1 form with the U.S. Securities and Exchange Commission (SEC) for its initial public offering (IPO). The company is offering 5.5 million American depositary shares ...
Read Full Story »
Medicine pills

Investors OK With Pfizer Earnings, Not OK With Guidance

Pfizer Inc. (NYSE: PFE) reported fourth-quarter and full-year 2015 results before markets opened Tuesday. The company reported quarterly adjusted diluted earnings per share (EPS) of $0.53 and revenues of $14.05 ...
Read Full Story »